Stockreport

Regen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024

Regen Biopharma, Inc. Common  (RGBP) 
NASDAQ:AMEX Investor Relations: regenbiopharmainc.com/investor-relations.html
PDF Regen BioPharma, Inc. invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging [Read more]